[November 25, 2014]

NHS England Proactively Rolls out Clinical Utilisation Review CQUIN 2015/16 Strategy

Medworxx Inc. ("Medworxx") (TSXV: MWX), a leader in clinical utilisation review (CUR) solutions, announced that NHS England has invited Medworxx to showcase their CUR solution at the National Clinical Utilisation Review Showcase and Training Event on December 11, 2014. Earlier this year the NHS England introduced a substantial Commissioning for Quality and Innovation scheme (CQUIN) to support providers in adopting CUR technology for specialised admitted patient care and critical care in 2015/16. The CQUIN demonstrates NHS England's commitment to CUR as an essential tool to effective patient flow within provider organisations and across local health economies and provides NHS Hospital Trusts with set-up funding and ongoing financial support and incentives to develop and embed recognised Clinical Utilisation Review systems. The goal is to improve patient flow, enhance quality and ensure patients are treated in the most appropriate clinical settings, freeing up staff time and hospital resources.

The showcase and training event is for NHS England area teams, hospital providers' clinicians and operational managers, and interested CCG leaders. "The CUR event emphasizes the value placed on the application of evidence based objective criteria in ensuring appropriate patient care whilst identifying opportunities for whole system transformation," stated, Peter Ellis, Managing Director of Medworxx UK. Medworxx plans to contribute to the National Clinical Utilisation Review event by showcasing user experience. Acute care providers from; Annapolis Valley Health Authority, Nova Scotia, Canada, Royal Liverpool and Broadgreen University Hospitals NHS Trust, UK, and South Tees Hospitals NHS Foundation Trust, UK, will speak about their experience using the Medworxx clinical utilisation solution.

Over the last 12 months more than 20 UK hospitals and their commissioners have used the Medworxx Clinical Utilisation Review capability through embedded and diagnostic applications. Patient Flow modules are used to inform patient flow improvement initiatives and to assess whole system improvement opportunities. Medworxx is the leading clinical utilization vendor in the UK and Canada with a combined total of over 29,500 licensed beds using Medworxx patient flow software. "As a clinical utilisation software provider it is gratifying to see that NHS England recogonises the value in these offerings and has created a risk-free environment by offering financial support to adopt CUR", said Dan Matlow, CEO and President, Medworxx. "Because of our success in Canada, which also has a single payer system, we are uniquely positioned and well matched to support a single payer based CUR strategy."

About Medworxx

Medworxx delivers health information technology solutions to over 350 hospitals internationally; including Canada, United States, United Kingdom, France and Australia. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Clinical Criteria -flagship of Medworxx Patient Flow that includes electronic bed management and independent assessment components-currently serves over 34% of the acute-care beds in Canada, and rapidly increasing number of Trusts and CCGs in the UK. Founded in 2004, Medworxx Inc. is based in Toronto, ON (News - Alert), and publicly traded on the TSX Venture Exchange: MWX.
Visit: www.medworxx.com

Disclaimer

The statements made in this press release may contain forward-looking statements that may involve a number of risks and uncertainties. Actual events or results could differ materially from the company's expectations and projections. The TSX Venture Exchange has not reviewed this press release and neither approved nor disapproved the information contained in this press release.

[ Back To TMCnet.com's Homepage ]